Evidence map›Paper›PMID 39804959›Full record

SynthesisPLoS medicine2025

Factors associated with tuberculosis treatment initiation among bacteriologically negative individuals evaluated for tuberculosis: An individual patient data meta-analysis.

Sun Kim, Melike Hazal Can, Tefera B Agizew, Andrew F Auld, Maria Elvira Balcells, Stephanie Bjerrum, Keertan Dheda, Susan E Dorman, Aliasgar Esmail, Katherine Fielding and 16 more

Abstract readMeta-AnalysisSystematic Review
In one paragraph

Synthesis in PLoS medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. TheFrontiers in medicine · 2026
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

26 authors.

Sun KimDepartment of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States of America.ORCID https://orcid.org/0000-0002-2466-2442
Melike Hazal CanDepartment of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States of America.ORCID https://orcid.org/0000-0001-6810-0356
Tefera B AgizewUS Centers for Disease Control and Prevention, Gaborone, Botswana.ORCID https://orcid.org/0000-0003-1848-7307
Andrew F AuldUS Centers for Disease Control and Prevention, Lusaka, Zambia.ORCID https://orcid.org/0000-0001-5089-9163
Maria Elvira BalcellsInfectious Disease Department, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile.ORCID https://orcid.org/0000-0002-7223-9665
Stephanie BjerrumDepartment of Clinical Research, University of Southern Denmark, Odense, Denmark.ORCID https://orcid.org/0000-0002-9046-6255
Keertan DhedaCentre for Lung Infection and Immunity, Division of Pulmonology, Department of Medicine and UCT Lung Institute, Cape Town, South Africa.
Susan E DormanMedical University of South Carolina, Charleston, South Carolina, United States of America.
Aliasgar EsmailCentre for Lung Infection and Immunity, Division of Pulmonology, Department of Medicine and UCT Lung Institute, Cape Town, South Africa.ORCID https://orcid.org/0000-0002-1835-9252
Katherine FieldingTB Centre, Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, United Kingdom.ORCID https://orcid.org/0000-0002-6524-3754
Alberto L Garcia-BasteiroISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Spain.ORCID https://orcid.org/0000-0002-2038-5505
Colleen F HanrahanEpidemiology Department, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America.ORCID https://orcid.org/0000-0002-4544-4591
Wakjira KebedeSchool of Medical Laboratory Sciences, Jimma University, Jimma, Ethiopia.ORCID https://orcid.org/0000-0003-4309-8143
Mikashmi KohliFIND, Geneva, Switzerland.
Anne F LuetkemeyerUniversity of California San Francisco, San Francisco, California, United States of America.ORCID https://orcid.org/0000-0003-0911-1578
Carol MitaCountway Library of Medicine, Harvard University, Boston, Massachusetts, United States of America.ORCID https://orcid.org/0000-0003-3059-1369
Byron W P ReeveDSI-NRF Centre of Excellence for Biomedical Tuberculosis Research and SAMRC Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, South Africa.
Denise Rossato SilvaFaculdade de Medicina, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.
Sedona SweeneyFaculty of Public Health and Policy, London School of Hygiene & Tropical Medicine, London, United Kingdom.ORCID https://orcid.org/0000-0003-4233-9080
Grant TheronDSI-NRF Centre of Excellence for Biomedical Tuberculosis Research and SAMRC Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, South Africa.ORCID https://orcid.org/0000-0002-9216-2415
Anete TrajmanFederal University of Rio de Janeiro, Rio de Janeiro, Brazil.ORCID https://orcid.org/0000-0002-4000-4984
Anna VassallCentre for Mathematical Modelling of Infectious Diseases, London School of Hygiene & Tropical Medicine, London, United Kingdom.
Joshua L WarrenDepartment of Biostatistics, Yale School of Public Health, New Haven, Connecticut, United States of America.ORCID https://orcid.org/0000-0002-6274-6970
Marcel YotebiengDivision of General Internal Medicine, Department of Medicine, Albert Einstein College of Medicine, New York City, New York, United States of America.ORCID https://orcid.org/0000-0003-2110-2631
Ted CohenDepartment of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, Connecticut, United States of America.ORCID https://orcid.org/0000-0002-8091-7198
Nicolas A MenziesDepartment of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States of America.ORCID https://orcid.org/0000-0002-2571-016X

Funding

FEND for TB supplement to accelerate BLINK X developmentU01AI152084 · NIAID · RUTGERS BIOMEDICAL AND HEALTH SCIENCES · PI ALLAND, DAVID, DORMAN, SUSAN E · 2020 to 2024
$20.0M
NIAID NIH HHS U01 AI152084
6 · The paper itself

Abstract

backgroundGlobally, over one-third of pulmonary tuberculosis (TB) disease diagnoses are made based on clinical criteria after a negative bacteriological test result. There is limited information on the factors that determine clinicians' decisions to initiate TB treatment when initial bacteriological test results are negative. METHODS AND

findingsWe performed a systematic review and individual patient data meta-analysis using studies conducted between January 2010 and December 2022 (PROSPERO: CRD42022287613). We included trials or cohort studies that enrolled individuals evaluated for TB in routine settings. In these studies, participants were evaluated based on clinical examination and routinely used diagnostics and were followed for ≥1 week after the initial test result. We used hierarchical Bayesian logistic regression to identify factors associated with treatment initiation following a negative result on an initial bacteriological test (e.g., sputum smear microscopy (SSM), Xpert MTB/RIF). Multiple factors were positively associated with treatment initiation: male sex [adjusted odds ratio (aOR) 1.61 (1.31, 1.95)], history of prior TB [aOR 1.36 (1.06, 1.73)], reported cough [aOR 4.62 (3.42, 6.27)], reported night sweats [aOR 1.50 (1.21, 1.90)], and having HIV infection but not on ART [aOR 1.68 (1.23, 2.32)]. Treatment initiation was substantially less likely for individuals testing negative with Xpert [aOR 0.77 (0.62, 0.96)] compared to smear microscopy and declined in more recent years. We were not able assess why clinicians made treatment decisions, as these data were not available.

conclusionsMultiple factors influenced decisions to initiate TB treatment despite negative test results. Clinicians were substantially less likely to treat in the absence of a positive test result when using more sensitive, PCR-based diagnostics.

Indexed as

Antitubercular AgentsTuberculosis, PulmonaryAdultFemaleHumansMaleMiddle AgedMycobacterium tuberculosisAntitubercular Agents

Identifiers

PMID39804959
PMCPMC11729971

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.